Sma Medical, INC.

Sma Medical, INC. was paid $20.44M by Medicaid between Jan 2018 and Dec 2024, across 262 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 16% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Pennsylvania

Rank by total paid#9 of 95

Median peer was paid$153K

This provider vs. median134×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	245,311	$2.26M
2019	185,392	$2.03M
2020	293,330	$4.05M
2021	334,304	$4.29M
2022	327,539	$3.86M
2023	195,701	$2.12M
2024incomplete	188,336	$1.82M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	16%	56,846	37,040	$3.22M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	12%	36,378	21,520	$2.35M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	6.7%	15,571	12,901	$1.38M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.9%	53,949	37,295	$1.21M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	5.2%	3,392	3,045	$1.06M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	4.8%	23,221	18,128	$991K
87150		3.4%	9,744	7,831	$703K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	2.3%	44,689	39,539	$472K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.0%	23,338	13,801	$405K
87481		1.4%	11,020	9,085	$291K
80061	Lipid panel	1.2%	56,179	49,991	$251K
84311		1.0%	77,780	51,148	$205K

250 more codes

84443	Thyroid stimulating hormone (TSH)	<1%	49,271	$201K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	15,597	$195K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	15,597	$195K
86235		<1%	2,177	$181K
82607		<1%	29,282	$172K
80050	General health panel	<1%	12,364	$163K
83036	Hemoglobin; glycosylated (A1C)	<1%	50,521	$159K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	13,421	$154K
82570		<1%	82,124	$143K
80053	Comprehensive metabolic panel	<1%	53,978	$139K
86003		<1%	1,162	$136K
87500		<1%	10,377	$132K
82746		<1%	19,018	$126K
87653		<1%	10,368	$117K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	58,366	$116K
80323		<1%	8,680	$115K
80354		<1%	9,457	$114K
80360		<1%	9,062	$112K
86769		<1%	3,511	$112K
80357		<1%	8,551	$111K
80171		<1%	7,931	$107K
80368		<1%	8,280	$105K
80369		<1%	7,783	$105K
80366		<1%	8,499	$104K
80342		<1%	7,984	$103K
87640		<1%	10,635	$102K
87486		<1%	3,906	$93K
87581		<1%	3,908	$93K
83090		<1%	12,556	$93K
80361		<1%	7,516	$91K
80372		<1%	6,521	$91K
80374		<1%	7,601	$91K
82728		<1%	15,330	$87K
80346		<1%	6,286	$85K
81226		<1%	1,041	$85K
80074		<1%	5,292	$85K
80356		<1%	6,618	$83K
84403		<1%	8,166	$83K
83018		<1%	2,870	$82K
80365		<1%	5,855	$77K
80348		<1%	6,488	$73K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	8,688	$73K
84439		<1%	21,665	$69K
86780		<1%	13,327	$69K
80373		<1%	5,546	$69K
83986		<1%	62,093	$68K
84480		<1%	9,682	$67K
81003		<1%	75,824	$66K
84466		<1%	10,769	$64K
80358		<1%	5,975	$64K
87641		<1%	5,033	$62K
80324		<1%	4,829	$61K
86708		<1%	13,321	$59K
87799		<1%	4,314	$58K
86704		<1%	13,308	$55K
81225		<1%	1,019	$52K
86706		<1%	13,568	$50K
86696		<1%	6,741	$50K
84153		<1%	7,997	$50K
82670		<1%	5,383	$49K
83704		<1%	5,300	$44K
83735		<1%	15,151	$42K
86800		<1%	4,141	$38K
86376		<1%	4,646	$38K
87086	Culture, bacterial; quantitative colony count, urine	<1%	14,357	$38K
87390		<1%	4,761	$35K
84144		<1%	4,976	$34K
86695		<1%	6,696	$33K
86705		<1%	7,771	$33K
83698		<1%	3,373	$32K
86709		<1%	7,654	$32K
82627		<1%	3,839	$31K
80350		<1%	3,449	$31K
82977		<1%	8,878	$31K
86141		<1%	7,793	$30K
84550		<1%	16,680	$30K
87340		<1%	7,991	$30K
83525		<1%	8,782	$30K
83001		<1%	4,201	$29K
84146		<1%	3,939	$28K
81231		<1%	453	$28K
84481		<1%	8,216	$28K
81227		<1%	471	$27K
84270		<1%	3,422	$27K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	6,033	$26K
83002		<1%	3,959	$26K
83540		<1%	9,280	$26K
84681		<1%	3,948	$26K
82300		<1%	2,796	$25K
81401		<1%	633	$25K
81230		<1%	300	$24K
82108		<1%	2,793	$24K
86038		<1%	3,602	$24K
84436		<1%	9,894	$24K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	602	$23K
83785		<1%	2,794	$23K
80335		<1%	1,553	$23K
86160		<1%	1,271	$22K
83695		<1%	9,348	$21K
80048	Basic metabolic panel (calcium, ionized)	<1%	6,276	$21K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	4,602	$20K
86702		<1%	4,772	$20K
83880		<1%	2,173	$19K
86225		<1%	2,184	$19K
81001		<1%	16,905	$19K
80076		<1%	4,296	$18K
84402		<1%	2,570	$18K
82985		<1%	1,484	$17K
87186		<1%	5,024	$17K
84154		<1%	2,645	$16K
82652		<1%	987	$16K
83721		<1%	12,262	$16K
83550		<1%	11,997	$16K
83885		<1%	1,907	$16K
82175		<1%	2,803	$16K
86618		<1%	1,315	$16K
83825		<1%	2,803	$15K
82248		<1%	6,858	$15K
83970		<1%	1,133	$15K
86701		<1%	4,764	$15K
82550		<1%	3,944	$15K
87088		<1%	4,386	$15K
81328		<1%	314	$15K
82043		<1%	6,812	$14K
87505		<1%	417	$14K
84255		<1%	995	$13K
84630		<1%	2,843	$13K
82525		<1%	2,819	$12K
83655		<1%	3,163	$12K
36415	Collection of venous blood by venipuncture	<1%	39,535	$12K
87350		<1%	3,225	$11K
84378		<1%	1,144	$11K
86707		<1%	3,075	$11K
80349		<1%	765	$11K
86803		<1%	1,737	$10K
86431		<1%	3,742	$9K
82785		<1%	745	$9K
86140		<1%	3,860	$9K
86703		<1%	1,876	$8K
82172		<1%	2,008	$8K
81223		<1%	17	$8K
87631		<1%	429	$8K
82542		<1%	1,717	$8K
80347		<1%	596	$7K
85651		<1%	3,297	$7K
80320		<1%	483	$6K
86256		<1%	1,235	$6K
82495		<1%	439	$6K
81400		<1%	607	$5K
81002		<1%	5,569	$5K
81291		<1%	220	$5K
83789		<1%	1,135	$5K
87652		<1%	415	$5K
83992		<1%	272	$5K
83516		<1%	715	$5K
84315		<1%	5,477	$5K
85045		<1%	1,831	$4K
80353		<1%	272	$4K
84479		<1%	4,335	$4K
81406		<1%	24	$4K
82150		<1%	2,218	$4K
82784		<1%	278	$4K
86301		<1%	223	$4K
84702		<1%	556	$4K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	282	$3K
82378		<1%	274	$3K
86804		<1%	513	$3K
81479	Unlisted molecular pathology procedure	<1%	283	$3K
83690		<1%	1,280	$3K
80364		<1%	183	$3K
86677		<1%	229	$3K
82725		<1%	819	$3K
83921		<1%	179	$3K
84100		<1%	1,861	$3K
81259		<1%	21	$2K
84482		<1%	937	$2K
85610		<1%	1,893	$2K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	200	$2K
80345		<1%	156	$2K
82533		<1%	798	$2K
81252		<1%	17	$2K
84425		<1%	273	$1K
82105		<1%	84	$1K
84207		<1%	112	$1K
86304		<1%	77	$1K
86592		<1%	760	$1K
84252		<1%	233	$1K
85046		<1%	531	$971.02
86300		<1%	55	$968.64
81250		<1%	17	$935.84
81243		<1%	17	$912.64
85730		<1%	501	$907.43
84140		<1%	130	$901.12
84445		<1%	67	$867.85
81255		<1%	17	$823.20
81251		<1%	17	$756.00
81200		<1%	17	$756.00
81330		<1%	17	$752.00
84156		<1%	574	$750.11
86901		<1%	331	$723.30
86900		<1%	330	$720.62
81290		<1%	17	$628.96
81260		<1%	17	$628.96
81209		<1%	17	$628.96
81405		<1%	20	$602.70
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	14	$557.58
80355		<1%	259	$552.23
81404		<1%	17	$549.66
84446		<1%	431	$525.05
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	815	$416.08
84590		<1%	196	$375.59
83876		<1%	47	$362.79
82947		<1%	113	$344.83
80164		<1%	145	$334.04
81005		<1%	323	$308.92
82787		<1%	14	$275.12
86694		<1%	45	$266.67
83615		<1%	487	$260.50
84591		<1%	247	$252.74
80352		<1%	54	$247.64
80069		<1%	520	$217.59
86039		<1%	44	$197.19
86762		<1%	28	$146.34
86787		<1%	27	$112.22
88112		<1%	78	$102.37
80178		<1%	16	$97.22
86735		<1%	14	$70.34
86765		<1%	14	$69.38
82610		<1%	13	$68.54
80177		<1%	14	$47.36
81242		<1%	20	$36.62
86850		<1%	14	$25.04
81015		<1%	88	$22.98
87147		<1%	15	$19.24
82553		<1%	14	$4.50
82180		<1%	93	$3.96
81205		0%	17	$0.00
0032U		0%	232	$0.00
81363		0%	17	$0.00
81355		0%	131	$0.00
81364		0%	17	$0.00
81232		0%	64	$0.00
80301		0%	12	$0.00
80336		0%	20	$0.00
81222		0%	17	$0.00
0033U		0%	232	$0.00
0031U		0%	232	$0.00
81350		0%	75	$0.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	45	$0.00
81254		0%	17	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialZHIVALYUK, KIRA (GENERAL MANAGER)